SCHEMBL5714899

SCHEMBL5714899

Cc1cccc(Cc2ccc(OC(=O)N3CCN(c4ccc(F)cn4)CC3)cc2)n1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PANK3 Q9H999 2/20 0.46
HRH3 Q9Y5N1 4/20 0.46
SMN1; SMN2 Q16637 2/20 0.42
HPGD P15428 1/20 0.42
SLC27A1 Q6PCB7 2/20 0.42
ALOX15 P16050 1/20 0.42
SMO Q99835 1/20 0.41
ME2 P23368 2/20 0.41
ME1 P48163 2/20 0.41
ME3 Q16798 2/20 0.41
PPARG P37231 1/20 0.40
CHRM1 P11229 1/20 0.40
GPR119 Q8TDV5 1/20 0.40
WNT3A P56704 1/20 0.39
KDM4E B2RXH2 1/20 0.39
ALDH1A1 P00352 1/20 0.39
LMNA P02545 1/20 0.39
TSHR P16473 1/20 0.39
HTT P42858 1/20 0.39
RAB9A P51151 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5715191 0.92 ME2 (0.45) PANK3HRH3SMN1; SMN2HPGDSLC27A1
SCHEMBL5714386 0.91 PANK3 (0.48) PANK3HRH3SMN1; SMN2HPGDSMO
SCHEMBL5715125 0.89 PANK3 (0.48) PANK3SMN1; SMN2HPGDSMOME2
SCHEMBL5714713 0.88 SMN1; SMN2 (0.59) HRH3SMN1; SMN2HPGDKDM4EALDH1A1
SCHEMBL5714825 0.88 PANK3 (0.46) PANK3HRH3SMN1; SMN2HPGDSMO
SCHEMBL5904417 0.88 HRH3 (0.46) PANK3HRH3SMN1; SMN2HPGDSMO
SCHEMBL5715393 0.86 SMO (0.47) PANK3HRH3SMN1; SMN2HPGDSMO
SCHEMBL5714653 0.86 HSD17B10 (0.53) SMN1; SMN2HPGDALOX15SMOKDM4E
SCHEMBL5714999 0.86 HSD17B10 (0.47) PANK3HRH3SMN1; SMN2HPGDALOX15
SCHEMBL5715035 0.85 PANK3 (0.48) PANK3HRH3SMN1; SMN2HPGDALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060160819-A1 Substitued piperazine carbamates NOVO NORDISK A/S (DK) 2006-07-20 US claimed
CN-1798735-A 1-aryl-4- (aryloxycarbonyl) -piperazine derivatives as inhibitors of hormone sensitive lipase NOVO NORDISK AS (DK) 2006-07-05 CN claimed
EP-1636189-A1 1-ARYL-4-(ARYLOXYCARBONYL)-PIPERAZINE DERIVATIVES FOR USE AS INHIBITORS OF HORMONE SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2006-03-22 EP claimed
WO-2004111007-A1 1-ARYL-4-(ARYLOXYCARBONYL)-PIPERAZINE DERIVATIVES FOR USE AS INHIBITORS OF HORMONE SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2004-12-23 WO claimed
CN-1798735-A 1-aryl-4- (aryloxycarbonyl) -piperazine derivatives as inhibitors of hormone sensitive lipase NOVO NORDISK AS (DK) 2006-07-05 CN disclosed
EP-1636189-A1 1-ARYL-4-(ARYLOXYCARBONYL)-PIPERAZINE DERIVATIVES FOR USE AS INHIBITORS OF HORMONE SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2006-03-22 EP disclosed
WO-2004111007-A1 1-ARYL-4-(ARYLOXYCARBONYL)-PIPERAZINE DERIVATIVES FOR USE AS INHIBITORS OF HORMONE SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2004-12-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060160819-A1 Substitued piperazine carbamates LIPE, PNLIP, LIPC PANK3 1247/4885HRH3 1098/4885SMN1; SMN2 2732/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.